Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

The NB.1.8.1 COVID-19 variant, dominant in China, is spreading in the U.S. via international travelers, with cases detected ...

The variant, first detected in the U.S. in late March, has now been identified in arriving international travelers through ...

The framework the new FDA leaders laid out on Tuesday raised small and big questions about the regulatory process, vaccine ...

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die ...

The vaccine is expected to remain available for anyone who is at least 65 or who has a medical condition, leaving many Americans ineligible. Here's what we know.

The US Food and Drug Administration has ordered Pfizer and Moderna to expand their warning labels on COVID-19 vaccines.

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

The U.S. has detected the NB.1.8.1 COVID-19 variant, dominant in China, through airport screenings and health departments ...

The travelers with cases linked to the NB.1.8.1 variant have been arriving at airports in California, Washington state, ...